false
0001708599
0001708599
2024-05-14
2024-05-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported): May 14, 2024
Serina
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
1-38519 |
|
82-1436829 |
(State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
incorporation) |
|
File
Number) |
|
Identification
No.) |
601
Genome Way, Suite 2001
Huntsville,
Alabama 35806
(Address
of principal executive offices)
(256)
327-9630
(Registrant’s
telephone number, including area code)
Not
applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of exchange on which registered |
Common
Stock, par value $0.0001 per share |
|
SER |
|
NYSE
American |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Explanatory
Note
On
March 26, 2024, the Delaware corporation formerly known as “AgeX Therapeutics, Inc.” completed its previously announced merger
transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of August 29,
2023 (the “Merger Agreement”), by and among AgeX Therapeutics, Inc. (“AgeX”), Canaria
Transaction Corporation, a wholly owned subsidiary of AgeX (“Merger Sub”), and Serina Therapeutics, Inc. (“Serina”),
pursuant to which Merger Sub merged with and into Serina, with Serina surviving the merger as a wholly owned subsidiary of AgeX (the
“Merger”). Additionally, on March 26, 2024, AgeX changed its name from “AgeX Therapeutics, Inc.”
to “Serina Therapeutics, Inc.” (the “Company”).
Item
2.02 Results of Operations and Financial Condition
On
May 14, 2024, the Company announced its financial results for the quarter ended March 31, 2024. The full text of the press release is
furnished as Exhibit 99.1 hereto.
The
information in the attached Exhibit 99.1 is being furnished pursuant to Item 2.02 “Results of Operations and Financial Condition”
on Form 8-K. The information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934
or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933 or the Securities Exchange Act of 1934, each as amended, except as shall be expressly set forth by specific reference in
such filing.
Item
9.01 - Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
SERINA
THERAPEUTICS, INC. |
|
|
|
Date:
May 14, 2024 |
By: |
/s/
Steven Ledger |
|
|
Interim
Chief Executive Officer |
Exhibit 99.1
Serina
Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
HUNTSVILLE,
May 14, 2024 (GLOBE NEWSWIRE) — Serina Therapeutics (“Serina”) (NYSE American: SER), a clinical-stage
biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today reported financial results for the
quarter ended March 31, 2024 and provided business highlights.
Recent
Highlights
|
● |
Advancement
of SER-252. The Company is advancing its lead drug candidate, SER-252 (POZ-apomorphine), for the treatment of advanced Parkinson’s
Disease. The Company anticipates submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration
with plans to initiate a Phase 1 clinical trial in 2025. |
|
|
|
|
● |
Completion
of merger with AgeX Therapeutics. The Company closed its merger with a wholly owned subsidiary of AgeX Therapeutics, Inc. The
management team of the combined company is led by Steven Ledger as Interim Chief Executive Officer. The combined company began trading
on the NYSE American market under the ticker symbol “SER” on March 27, 2024. |
|
|
|
|
● |
Appointment
of Dr. Simba Gill as Executive Chairman. Dr. Gill brings a wealth of biotech and pharma experience in building companies
and transformative platforms as well as developing products, having served in key roles at Maxygen, Systemix, Boehringer Mannheim
and Celltech. He earned his MBA at INSEAD and received his Ph.D. from King’s College, London. Dr. Gill will play a pivotal
role in guiding Serina through its next phase of growth and development, leveraging his expertise to drive strategic expansion initiatives. |
Liquidity
and Capital Resources
Increase
in Line of Credit
On
March 26, 2024, the Company’s secured, convertible line of credit from Juvenescence Limited was increased by $2,400,000, which
was drawn entirely on March 29, 2024.
On
May 8, 2024, the repayment date of the Company’s borrowings under the Juvenescence line of credit was extended from May 9, 2024
to December 31, 2024 and the line of credit increased by an additional $525,000 which we received entirely on May 9, 2024.
Balance
Sheet Information
Cash,
cash equivalents, and restricted cash totaled $8.8 million as of March 31, 2024. As of March 31, 2024, the Company owed Juvenescence
Limited $10.4 million in principal and origination fees on account of loans extended to the Company.
First
Quarter 2023 Operating Results
Revenues:
Revenues comprised entirely of grant revenues in the amount of $5,000 and $30,000 for the first quarter of 2024 and in the same period
in 2023, respectively.
Operating
expenses: Operating expenses for the three months ended March 31, 2024 were $2.3 million, as compared with $1 million for the same
period in 2023.
Research
and development expenses for the three months ended March 31, 2024 increased by approximately $0.7 million to $1.1 million from $0.4
million during the same period in 2023. The net increase was primarily attributable to increases of $0.5 million in outside research
and services allocable to research and development expenses, $0.1 million in patent related professional fees, and $0.1 million in salaries
and payroll related expenses and consulting services allocable to research and development expenses.
General
and administrative expenses for the three months ended March 31, 2024 increased by $0.6 million to $1.2 million as compared to $0.6 million
during the same period in 2023. The net increase is attributable to increases of $0.5 million in professional legal and accounting services
incurred in connection with the Merger which consummated on March 26, 2024, $0.1 million in consulting services and noncash stock-based
compensation to consultants allocable to general and administrative expenses, and $0.1 million in investment and public relations related
expenses. These increases were offset to some extent by a $0.1 million decrease for database subscription fee.
Other
expense, net: Net other expense for the three months ended March 31, 2024 is primarily comprised of $7 million change in fair value
of convertible promissory notes which was converted to common stock on March 26, 2024.
Net
loss: The net loss for the three months ended March 31, 2024 was $9.4 million, or ($3.38) per share (basic and diluted) compared
to net income of $1.7 million, or $0.77 per share (basic) and $0.20 per share (diluted), for 2023. Net loss for the three months ended
March 31, 2024 as compared to net income in 2023 is partially attributable to expenses related to the Merger which consummated on March
26, 2024 and net change in fair value of convertible promissory notes and warrants.
Going
Concern Considerations
As
required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), the Company
evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they
become due within one year after the date its financial statements are issued. Based on the Company’s most recent projected cash
flows, the Company believes that its cash and cash equivalents and the additional $0.5 million borrowings from Juvenescence received
on May 9, 2024 would not be sufficient to satisfy the Company’s anticipated operating and other funding requirements for the twelve
months following the filing of the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2024. These factors
raise substantial doubt regarding the ability of the Company to continue as a going concern.
About
SER-252 (POZ-apomorphine)
SER
252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous
dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in
Parkinson’s disease. Preclinical studies support the potential of SER 252 to provide CDS without skin reactions. Serina plans
to advance SER 252 to clinical testing in 2025.
About
the POZ Platform™
Serina’s
proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Serina’s POZ
technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered
via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs
that are effective but are limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life. Serina believes
that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the
blood.
Serina’s
POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional
applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license
agreement with Pfizer, Inc. to use Serina’s POZ polymer technology for use in lipid nanoparticle drug (LNP) delivery formulations.
About
Serina Therapeutics
Serina
is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases
and pain. Serina’s POZ PlatformTM delivery technology is engineered to provide greater control in drug loading and more
precision in the rate of release of attached drugs, enabling the potential of challenging small molecules, while addressing the limitations
of PEG (polyethylene glycol) and other biocompatible polymers. In addition, our POZ PlatformTM partners are at the forefront
in advancing lipid nanoparticle (LNP) delivery technology to develop novel RNA therapeutics. Serina is headquartered in Huntsville, Alabama
on the campus of the HudsonAlpha Institute of Biotechnology.
For
more information, please visit https://serinatherapeutics.com.
Cautionary
Statement Regarding Forward-Looking Statement
This
release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management’s
current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express
or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina’s
POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results
to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties
inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates
for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable
new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations
and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical
studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory
authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will
depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and
determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful;
decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability
or commercial potential of any drug or vaccine candidates; uncertainties regarding the impact of COVID-19 on Serina’s business,
operations and financial results; and competitive developments. These risks as well as other risks are more fully discussed in the company’s
Annual Report on Form 10-K for the year ended December 31, 2023, the company’s Current Report on Form 8-K that was filed with the
SEC on April 1, 2024, and the company’s other periodic reports and documents filed from time to time with the SEC.
The
Information contained in this release Is as of the date hereof, and Serina assumes no obligation to update forward-looking statements
contained in this release as the result of new information or future events or developments.
SERINA
THERAPEUTICS, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED BALANCE SHEETS
(in
thousands, except par value amounts)
(unaudited)
| |
March 31,
2024 | | |
December 31, 2023 | |
ASSETS | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 8,706 | | |
$ | 7,619 | |
Accounts and grants receivable, net | |
| 65 | | |
| - | |
Prepaid expenses and other current assets | |
| 166 | | |
| - | |
Total current assets | |
| 8,937 | | |
| 7,619 | |
| |
| | | |
| | |
Restricted cash | |
| 50 | | |
| - | |
Property and equipment, net | |
| 564 | | |
| 573 | |
Right of use assets - operating leases | |
| 627 | | |
| 666 | |
Right of use assets - finance leases | |
| 104 | | |
| 110 | |
Intangible assets, net | |
| 574 | | |
| - | |
TOTAL ASSETS | |
$ | 10,856 | | |
$ | 8,968 | |
| |
| | | |
| | |
LIABILITIES, REDEEMABLE CONVERTIBLE PREFFERED STOCK, AND STOCKHOLDERS’ DEFICIT | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable and accrued liabilities | |
$ | 4,013 | | |
$ | 1,163 | |
Loans due to Juvenescence, net of debt issuance costs | |
| 9,746 | | |
| - | |
Related party payables, net | |
| 66 | | |
| - | |
Current portion of operating lease liabilities | |
| 207 | | |
| 214 | |
Current portion of finance lease liabilities | |
| 24 | | |
| 36 | |
Other current liabilities | |
| 3 | | |
| - | |
Total current liabilities | |
| 14,059 | | |
| 1,413 | |
| |
| | | |
| | |
Loans due to Juvenescence | |
| 693 | | |
| - | |
Convertible promissory notes, at fair value | |
| - | | |
| 2,983 | |
Operating lease liabilities, net of current portion | |
| 413 | | |
| 461 | |
Finance lease liabilities, net of current portion | |
| - | | |
| 1 | |
TOTAL LIABILITIES | |
| 15,165 | | |
| 4,858 | |
| |
| | | |
| | |
Commitments and contingencies | |
| | | |
| | |
| |
| | | |
| | |
Redeemable Convertible Preferred Stock: | |
| | | |
| | |
Redeemable convertible preferred stock, $0.01 par value; 10,000 authorized; nil and 3,438 issued and outstanding at March 31, 2024 and December 31, 2023, respectively | |
| - | | |
| 36,404 | |
| |
| | | |
| | |
Stockholders’ deficit: | |
| | | |
| | |
Preferred stock, $0.0001 par value, 5,000 shares authorized; none issued and outstanding | |
| - | | |
| - | |
| |
| | | |
| | |
Common stock, $0.0001 par value, 40,000 shares authorized; and 8,414 and 2,410 shares issued and outstanding | |
| 1 | | |
| 25 | |
Additional paid-in capital | |
| 1,125 | | |
| 858 | |
Accumulated deficit | |
| (5,435 | ) | |
| (33,177 | ) |
Total stockholders’ deficit | |
| (4,309 | ) | |
| (32,294 | ) |
TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS’
DEFICIT | |
$ | 10,856 | | |
$ | 8,968 | |
SERINA
THERAPEUTICS, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(in
thousands, except par value amounts)
(unaudited)
| |
Three Months
Ended March 31, | |
| |
2024 | | |
2023 | |
REVENUES | |
| | | |
| | |
Grant revenues | |
$ | 5 | | |
$ | 30 | |
Total revenues | |
| 5 | | |
| 30 | |
| |
| | | |
| | |
OPERATING EXPENSES | |
| | | |
| | |
Research and development | |
| 1,106 | | |
| 399 | |
General and administrative | |
| 1,220 | | |
| 593 | |
Total operating expenses | |
| 2,326 | | |
| 992 | |
| |
| | | |
| | |
Loss from operations | |
| (2,321 | ) | |
| (962 | ) |
| |
| | | |
| | |
OTHER INCOME (EXPENSE), NET: | |
| | | |
| | |
Interest expense, net | |
| (99 | ) | |
| (86 | ) |
Fair value inception adjustment on convertible promissory note | |
| - | | |
| 2,240 | |
Change in fair value of convertible promissory notes | |
| (7,017 | ) | |
| 294 | |
Change in fair value of warrants | |
| - | | |
| 172 | |
Total other income (expense), net | |
| (7,116 | ) | |
| 2,620 | |
| |
| | | |
| | |
NET INCOME (LOSS) | |
$ | (9,437 | ) | |
$ | 1,658 | |
| |
| | | |
| | |
NET EARNINGS (LOSS) PER COMMON SHARE: | |
| | | |
| | |
BASIC | |
$ | (3.38 | ) | |
$ | 0.77 | |
DILUTED | |
$ | (3.38 | ) | |
$ | 0.20 | |
| |
| | | |
| | |
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: | |
| | | |
| | |
BASIC | |
| 2,790 | | |
| 2,167 | |
DILUTED | |
| 2,790 | | |
| 8,569 | |
For
inquiries, please contact:
Investor.relations@serinatherapeutics.com
(256)
327-9630
v3.24.1.1.u2
Cover
|
May 14, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
May 14, 2024
|
Entity File Number |
1-38519
|
Entity Registrant Name |
Serina
Therapeutics, Inc.
|
Entity Central Index Key |
0001708599
|
Entity Tax Identification Number |
82-1436829
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
601
Genome Way
|
Entity Address, Address Line Two |
Suite 2001
|
Entity Address, City or Town |
Huntsville
|
Entity Address, State or Province |
AL
|
Entity Address, Postal Zip Code |
35806
|
City Area Code |
(256)
|
Local Phone Number |
327-9630
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, par value $0.0001 per share
|
Trading Symbol |
SER
|
Security Exchange Name |
NYSEAMER
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
true
|
Entity Information, Former Legal or Registered Name |
Not
applicable
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Serina Therapeutics (AMEX:SER)
Historical Stock Chart
From Dec 2024 to Jan 2025
Serina Therapeutics (AMEX:SER)
Historical Stock Chart
From Jan 2024 to Jan 2025